Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. With the data to train, the AI to create, and the wet lab to validate, our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.
Company profile
Ticker
ABSI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb ...
Former names
AbSci, LLC
SEC CIK
Corporate docs
Subsidiaries
AbSci, LLC • Absci GmbH • Target Discovery Merger Sub II, LLC • De Novo Design, LLC • Absci Ltd • Absci d.o.o. ...
IRS number
453931977
ABSI stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
14 May 24
ARS
2024 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
21 Mar 24
8-K
Absci Announces Proposed Public Offering of Common Stock
28 Feb 24
424B5
Prospectus supplement for primary offering
28 Feb 24
Latest ownership filings
4
Sean McClain
21 Mar 24
4
Jeremy Green
5 Mar 24
SC 13D/A
Redmile Group, LLC
5 Mar 24
SC 13G/A
Phoenix Venture Partners II LP
14 Feb 24
5
Annual statement of changes in insider ownership
14 Feb 24
SC 13G
McClain Sean
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Todd Bedrick
5 Feb 24
4
Andreas Busch
5 Feb 24
4
Zachariah Jonasson
5 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 76.31 mm | 76.31 mm | 76.31 mm | 76.31 mm | 76.31 mm | 76.31 mm |
Cash burn (monthly) | 4.45 mm | (no burn) | 7.83 mm | 9.54 mm | 5.95 mm | 5.20 mm |
Cash used (since last report) | 6.63 mm | n/a | 11.65 mm | 14.20 mm | 8.86 mm | 7.73 mm |
Cash remaining | 69.68 mm | n/a | 64.65 mm | 62.11 mm | 67.45 mm | 68.57 mm |
Runway (months of cash) | 15.6 | n/a | 8.3 | 6.5 | 11.3 | 13.2 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 10 |
Closed positions | 33 |
Increased positions | 13 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 76.55 bn |
Total shares | 163.27 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Phoenix Venture Partners II | 144.93 mm | $0.00 |
FMR | 13.86 mm | $58.22 bn |
Platinum Investment Management | 837.60 k | $3.52 bn |
HBCYF HSBC | 407.58 k | $1.77 bn |
Royce & Associates | 387.77 k | $1.63 bn |
Charles Schwab Investment Management | 357.01 k | $1.50 bn |
Bridgeway Capital Management | 270.50 k | $1.14 bn |
Jane Street | 244.83 k | $1.03 bn |
Institute for Wealth Management | 242.88 k | $1.02 bn |
Allen Operations | 236.13 k | $991.74 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Mar 24 | Sean McClain | Common Stock | Grant | Acquire A | No | No | 0 | 1,500,000 | 0.00 | 8,225,955 |
1 Mar 24 | Redmile | Common Stock | Buy | Acquire P | Yes | No | 4.5 | 222,222 | 1,000.00 k | 8,253,316 |
1 Feb 24 | Sean McClain | Common Stock | Grant | Acquire A | No | No | 0 | 182,000 | 0.00 | 6,725,955 |
1 Feb 24 | Sean McClain | Stock Option Common Stock | Grant | Acquire A | No | No | 4.4 | 766,000 | 3.37 mm | 766,000 |
1 Feb 24 | Zachariah Jonasson | Common Stock | Grant | Acquire A | No | No | 0 | 114,010 | 0.00 | 375,910 |
1 Feb 24 | Zachariah Jonasson | Stock Option Common Stock | Grant | Acquire A | No | No | 4.4 | 479,570 | 2.11 mm | 479,570 |
1 Feb 24 | Andreas Busch | Common Stock | Grant | Acquire A | No | No | 0 | 83,125 | 0.00 | 258,125 |
1 Feb 24 | Andreas Busch | Stock Option Common Stock | Grant | Acquire A | No | No | 4.4 | 349,625 | 1.54 mm | 349,625 |
News
The Analyst Verdict: Absci In The Eyes Of 6 Experts
15 May 24
HC Wainwright & Co. Reiterates Buy on Absci, Maintains $7 Price Target
15 May 24
Absci Q1 2024 GAAP EPS $(0.22) Misses $(0.21) Estimate, Sales $898.000K Miss $2.419M Estimate
14 May 24
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
9 Apr 24
Truist Securities Maintains Buy on Absci, Maintains $9 Price Target
26 Mar 24
Press releases
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
14 May 24
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
16 Apr 24
Thinking about buying stock in Curiositystream, Capricor Therapeutics, PowerFleet, Absci, or Nano-X Imaging?
25 Mar 24
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
21 Mar 24
Latest Updates of Viva Biotech's Portfolio Companies
6 Mar 24